Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event
Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has two preclinical small molecule portfolios in development, one is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system, the other portfolio targets the metabolism of tumors. For more information, visit the company’s website at www.moleculin.com. About…







